Stocks
Merck & Company Holds Steady with Neutral Ratings from Major Analysts
RBC Capital analyst Trung Huynh has maintained a Hold rating on Merck & Company since September 29, setting a price target of $150.00 for the stock.
The company's shares closed at $149.28 on the same day, just shy of the target price set by Huynh.
Notably, Huynh has an impressive track record in the Healthcare sector, with a 76.51% success rate and an average return of 22.2% on recommended stocks, according to TipRanks.
In addition to RBC Capital's Hold rating, Merck & Company also received a similar assessment from Citi's Geoff Meacham in a report issued the same day.